{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:30:33Z","timestamp":1785148233660,"version":"3.55.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,5]]},"DOI":"10.7759\/cureus.110286","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:09:46Z","timestamp":1780657786000},"source":"Crossref","is-referenced-by-count":1,"title":["Asymptomatic Pembrolizumab-Associated Hypertriglyceridemia"],"prefix":"10.7759","author":[{"given":"Lauren S","family":"Yeager","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph G","family":"Zinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonglin","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Keytruda\u00ae [package insert]. (2020). https.\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125514s096lbl.pdf."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241245332","article-title":"Acute pancreatitis associated with pembrolizumab-induced hypertriglyceridemia","volume":"30","author":"Inayat F","year":"2024","unstructured":"Inayat F, Afzal A, Anwar MS, et al.. Acute pancreatitis associated with pembrolizumab-induced hypertriglyceridemia. J Oncol Pharm Pract. 2024, 30:1101-10. 10.1177\/10781552241245332","journal-title":"J Oncol Pharm Pract"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00245","article-title":"Pembrolizumab and severe hypertriglyceridemia requiring apheresis: an immune-related adverse event","volume":"15","author":"Thakker M","year":"2019","unstructured":"Thakker M, Quadri K, Desai A, Illyas W, Kim MY, Desai S, Rager C. Pembrolizumab and severe hypertriglyceridemia requiring apheresis: an immune-related adverse event. J Oncol Pract. 2019, 15:613-4. 10.1200\/JOP.19.00245","journal-title":"J Oncol Pract"},{"key":"ref4","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. U.S Department of Health and Human Services. (2017). https.\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611930","article-title":"Autoantibodies against GPIHBP1 as a cause of hypertriglyceridemia","volume":"376","author":"Beigneux AP","year":"2017","unstructured":"Beigneux AP, Miyashita K, Ploug M, et al.. Autoantibodies against GPIHBP1 as a cause of hypertriglyceridemia. N Engl J Med. 2017, 376:1647-58. 10.1056\/NEJMoa1611930","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.38315","article-title":"Acute pancreatitis secondary to pembrolizumab-induced hypertriglyceridemia","volume":"15","author":"Ashfaq A","year":"2023","unstructured":"Ashfaq A, Thalambedu N, Atiq MU. Acute pancreatitis secondary to pembrolizumab-induced hypertriglyceridemia. Cureus. 2023, 15:e38315. 10.7759\/cureus.38315","journal-title":"Cureus"},{"key":"ref8","unstructured":"Tricor\u00ae [package insert]. (2018). https.\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021656s029lbl.pdf."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/486969-asymptomatic-pembrolizumab-associated-hypertriglyceridemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:09:49Z","timestamp":1780657789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/486969-asymptomatic-pembrolizumab-associated-hypertriglyceridemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.110286","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,5]]}}}